Takeda To Reclaim Sales Rights To Actos, Create Own Networks
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical plans to take back the sales rights to its key diabetes drug from Eli Lilly and create its own sales network in most of Europe, Canada and other countries outside Japan. Takeda already does its own selling of Actos (pioglitazone) in the United States, United Kingdom, France and other countries. Lilly had been marketing the drug in countries where Takeda lacked a sales network. Seven countries besides Canada are involved in the takeback--Belgium, Denmark, Luxembourg, Norway, Sweden and Turkey. (Click here for more - a subscription may be required
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.